Top Page
Arecor Therapeutics PLC
(LSE:AREC)
Arecor Therapeutics PLC (AREC) vs. S&P 500 (SPY)
Arecor Therapeutics PLC Business Overview & Revenue Model
Arecor Therapeutics PLC Financial Statement Overview
| Breakdown | ||||
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 4.57M | 2.40M | 1.16M | 1.70M | 1.89M | Gross Profit |
| 4.57M | 2.06M | 1.16M | 1.70M | 1.89M | EBIT |
| -9.18M | -10.63M | -5.98M | -3.43M | -2.69M | EBITDA |
| -8.39M | -10.06M | -6.27M | -3.26M | -2.61M | Net Income Common Stockholders |
| -8.55M | -9.26M | -6.17M | -2.75M | -2.19M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 6.75M | 12.81M | 18.32M | 2.90M | 3.07M | Total Assets |
| 15.38M | 21.77M | 20.92M | 4.28M | 4.31M | Total Debt |
| 338.00K | 288.00K | 231.00K | 2.00M | 60.39K | Net Debt |
| -4.75M | -4.48M | -18.09M | -903.11K | -3.01M | Total Liabilities |
| 5.85M | 4.31M | 2.37M | 3.51M | 1.10M | Stockholders Equity |
| 9.53M | 17.45M | 18.55M | 773.79K | 3.21M |
| Cash Flow | Free Cash Flow | |||
| -5.99M | -11.13M | -5.52M | -1.91M | -491.10K | Operating Cash Flow |
| -5.84M | -10.78M | -5.45M | -1.86M | -458.80K | Investing Cash Flow |
| 6.52M | -7.99M | -68.00K | -49.32K | -22.89K | Financing Cash Flow |
| -180.00K | 5.16M | 20.93M | 1.77M | -131.02K |
Arecor Therapeutics PLC Technical Analysis
Arecor Therapeutics PLC Peers Comparison
Arecor Therapeutics PLC Corporate Events
Arecor Therapeutics plc has released its Annual Report and Accounts for the year ending December 31, 2024, and announced its Annual General Meeting scheduled for June 2, 2025. This announcement provides shareholders with updated financial information and strategic insights, potentially impacting investor confidence and the company’s market positioning.
Spark’s Take on GB:AREC Stock
According to Spark, TipRanks’ AI Analyst, GB:AREC is a Neutral.
Arecor Therapeutics PLC’s stock score reflects its growth potential in the biotech sector, bolstered by strategic partnerships and revenue growth. However, significant financial challenges, including ongoing losses and cash flow issues, weigh heavily on the score. Technical indicators also suggest bearish momentum, with the stock appearing oversold. The valuation remains unattractive due to a negative P/E ratio and lack of dividends. These factors collectively contribute to a cautious outlook despite promising corporate developments.
To see Spark’s full report on GB:AREC stock, click here.
Arecor Therapeutics plc announced that its CEO, Sarah Howell, and CFO, David Ellam, will present the company’s final results for the year ended 31 December 2024 on the Investor Meet Company platform on 1 May 2025. This presentation is accessible to both existing and potential shareholders, allowing them to submit questions in advance or during the live session. This initiative reflects Arecor’s commitment to transparency and engagement with its stakeholders, potentially enhancing its market presence and investor relations.
Arecor Therapeutics plc announced the grant of 230,000 options to its Chief Financial Officer, David Ellam, under the company’s Long Term Incentive Plan and All Employee Share Ownership Plan. This move is part of Arecor’s strategy to incentivize and retain key management personnel, potentially impacting the company’s operational focus and aligning management interests with shareholder value.
Arecor Therapeutics reported its final results for 2024, highlighting significant progress in its diabetes portfolio and the potential for innovation in oral peptide delivery. The company achieved a total revenue of £5.1 million, with advancements in its ultra-concentrated insulin candidate, AT278, and a new collaboration for oral peptide delivery. Despite a loss after tax of £10.2 million, Arecor remains focused on high-value R&D opportunities and expanding its partnership portfolio, positioning itself for future growth and success.
Arecor Therapeutics plc announced it will release its audited final results for the year ended 31 December 2024 on 22 April 2025. The announcement will include an in-person briefing for analysts, along with a live webcast and conference call, indicating the company’s commitment to transparency and engagement with stakeholders.
Arecor Therapeutics has entered into a collaboration with a major global pharmaceutical company to develop a novel formulation of the partner’s proprietary product using Arecor’s Arestat™ technology. This partnership, which is fully funded by the partner, underscores Arecor’s leadership in drug delivery and formulation innovation, potentially leading to future licensing opportunities and enhancing its market positioning.
Arecor Therapeutics plc has announced a collaboration with a clinical-stage biopharmaceutical company to develop a novel formulation of peptide therapy using its Arestat™ technology platform. This partnership, which includes funding for development and an option for the partner to license the new formulation, underscores Arecor’s leadership in the peptide therapeutics market, a sector projected to exceed $100 billion by 2034. The collaboration aims to leverage Arecor’s expertise in creating advanced peptide formulations, addressing unmet patient needs in a rapidly growing market driven by the rise of endocrine and metabolic diseases.